This randomized phase II trial studies how well pembrolizumab works in treating patients with
high risk oral intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread.